ABSTRACT
With the rise of two-dimensional nanomaterials in medicine, finding suitable materials has become our top priority. Since the first report of antimonene in 2015, due to its excellent physical and chemical properties, it has gradually attracted widespread attention, including its application prospects in cancer treatment. In this paper, the preparation, stability and infrared degradability of antimonene, as well as its experimental examples in tumor treatment in recent years are reviewed, the latest research results are listed and summarized, the advantages and existing problems are analyzed, and the future of antimonene in tumor therapy is prospected.
Subject(s)
Antimony/therapeutic use , Calcium Compounds/therapeutic use , Nanostructures/therapeutic use , Neoplasms/therapy , Precision Medicine , Animals , Heterografts , HumansABSTRACT
The in situ gelling hybrid hydrogel system has been reported to effectively concentrate chemotherapeutic drugs at the tumor site and sustain their release for a long period. DTX-micelles (docetaxel-loaded mixed micelles) are able to increase the solubility of DTX in water, and then a high drug loading rate of hydrogels can be achieved by encapsulating the docetaxel-loaded mixed micelles into the hydrogels. The thermosensitive nature of DTX-MM-hydrogels (thermosensitive hydrogels incorporated with docetaxel-loaded mixed micelles) can accelerate the formation of a depot of this drug-loaded system at the site of administration. Therefore, the hydrogels provide a much slower release compared with DTX-micelles and DTX-injection. An in vivo retention study has demonstrated that the DTX-MM-hydrogels can prolong the drug retention time and in vivo trials have shown that the DTX-MM-hydrogels have a higher antitumor efficacy and systemic safety. In conclusion, the DTX-MM-hydrogels prepared in this study have considerable potential as a drug delivery system, with higher tumor inhibition effects and are less toxic to normal tissues.
